Join the community - networking, discussion and more. Open to all.
More informationCould you write an interesting article for the RQA community?
More informationAn at-a-glance summary of news from around the agency
The warning letter summarises significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. 3. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Extended from 1 September 2024 until 31 August 2025.
Proposals on ongoing cost recovery
MHRA have published information on the implementation of changes to pharmacovigilance for medicines authorised in the UK following the agreement of the Windsor Framework.
New global guidance released
MHRA performance metrics for clinical trials and established medicines assessment.
New adopted and draft guidelines relating to Veterinary Products
New Guidance Published